2,724 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Western Financial Corp CA

Western Financial Corp CA bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,724 shares of the biopharmaceutical company’s stock, valued at approximately $1,242,000.

Several other hedge funds and other institutional investors have also made changes to their positions in ALNY. Salomon & Ludwin LLC bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at about $27,000. Atlantic Union Bankshares Corp acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $30,000. Elevation Point Wealth Partners LLC bought a new stake in Alnylam Pharmaceuticals during the second quarter worth approximately $37,000. Hilltop National Bank bought a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at $41,000. Finally, Ameritas Advisory Services LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $42,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the completion of the sale, the executive vice president owned 21,264 shares of the company’s stock, valued at $9,615,155.52. This trade represents a 36.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 15,650 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $453.69, for a total transaction of $7,100,248.50. Following the completion of the transaction, the chief executive officer owned 65,409 shares in the company, valued at approximately $29,675,409.21. This trade represents a 19.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 37,778 shares of company stock worth $17,096,988 in the last ninety days. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $400.17 on Friday. The firm’s 50 day moving average price is $432.07 and its two-hundred day moving average price is $417.39. The firm has a market cap of $52.87 billion, a P/E ratio of 1,667.38 and a beta of 0.32. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55.

Analysts Set New Price Targets

Several research firms recently commented on ALNY. Oppenheimer reissued an “outperform” rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. Wells Fargo & Company boosted their price objective on shares of Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Jefferies Financial Group lowered their target price on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a report on Thursday, October 30th. HC Wainwright set a $570.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 8th. Twenty-three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $477.44.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.